仿制药-话题@MedSci

#仿制药#

261篇内容 | 5510人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1261314, encodeId=a4b81261314ae, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=代文仿制药终获FDA批准, objectType=article, longId=37291, objectId=de8b3e29114, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de8b3e29114, replyNumber=0, likeNumber=83, createdTime=2014-07-04, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de8b3e29114, moduleTitle=代文仿制药终获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de8b3e29114)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261313, encodeId=68c112613137d, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药产业2015年市场规模或达5千亿, objectType=article, longId=37243, objectId=42cb3e243f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42cb3e243f1, replyNumber=0, likeNumber=72, createdTime=2014-07-03, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42cb3e243f1, moduleTitle=仿制药产业2015年市场规模或达5千亿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42cb3e243f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261312, encodeId=f6121261312a5, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=从全球看中国仿制药市场投资机会, objectType=article, longId=36918, objectId=f9bb3691817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9bb3691817, replyNumber=0, likeNumber=65, createdTime=2014-06-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9bb3691817, moduleTitle=从全球看中国仿制药市场投资机会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9bb3691817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261311, encodeId=971a126131109, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=英国法院裁决阿特维斯培美曲塞仿制药不侵犯礼来专利权, objectType=article, longId=35112, objectId=85dc3511216, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85dc3511216, replyNumber=0, likeNumber=58, createdTime=2014-05-24, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85dc3511216, moduleTitle=英国法院裁决阿特维斯培美曲塞仿制药不侵犯礼来专利权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85dc3511216)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261310, encodeId=cafd126131063, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=诺华提请禁止印度百康推出其维格列汀仿制药, objectType=article, longId=33255, objectId=4d633325514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d633325514, replyNumber=0, likeNumber=83, createdTime=2014-04-13, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d633325514, moduleTitle=诺华提请禁止印度百康推出其维格列汀仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d633325514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261309, encodeId=fb8b126130989, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=梯瓦Evista仿制药获FDA批准, objectType=article, longId=31516, objectId=43cf315167e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cf315167e, replyNumber=0, likeNumber=60, createdTime=2014-03-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cf315167e, moduleTitle=梯瓦Evista仿制药获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43cf315167e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261308, encodeId=19b512613086f, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=仿制药质量一致性评价马上推进, objectType=article, longId=30716, objectId=b73530e16a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b73530e16a8, replyNumber=0, likeNumber=53, createdTime=2014-02-19, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b73530e16a8, moduleTitle=仿制药质量一致性评价马上推进, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b73530e16a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261307, encodeId=1aff126130efb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=罗氏禁止仿制药对手使用赫赛汀进行对照, objectType=article, longId=30538, objectId=e5d6305381e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5d6305381e, replyNumber=0, likeNumber=66, createdTime=2014-02-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5d6305381e, moduleTitle=罗氏禁止仿制药对手使用赫赛汀进行对照, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5d6305381e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261306, encodeId=6a931261306c3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=全球仿制药巨头为何退出中国, objectType=article, longId=30384, objectId=3fc1303849a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc1303849a, replyNumber=0, likeNumber=76, createdTime=2014-02-11, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc1303849a, moduleTitle=全球仿制药巨头为何退出中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc1303849a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261305, encodeId=4eee1261305bd, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=巨头卡位：谁将抢下全球仿制药**把交椅？, objectType=article, longId=29524, objectId=37ad29524a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37ad29524a8, replyNumber=0, likeNumber=40, createdTime=2014-01-19, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37ad29524a8, moduleTitle=巨头卡位：谁将抢下全球仿制药**把交椅？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37ad29524a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261304, encodeId=cb7412613047c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=品牌仿制药：迎来行业发展新契机, objectType=article, longId=27957, objectId=0a252e957e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a252e957e5, replyNumber=0, likeNumber=52, createdTime=2013-12-14, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a252e957e5, moduleTitle=品牌仿制药：迎来行业发展新契机, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a252e957e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261303, encodeId=13eb1261303b8, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA向仿制药商增收费用印度制药商成本增加, objectType=article, longId=23239, objectId=9fdb2323926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdb2323926, replyNumber=0, likeNumber=90, createdTime=2013-08-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdb2323926, moduleTitle=FDA向仿制药商增收费用印度制药商成本增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fdb2323926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261302, encodeId=99351261302f2, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=格列卫仿制药的未来之路, objectType=article, longId=21809, objectId=bb922180965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb922180965, replyNumber=0, likeNumber=79, createdTime=2013-07-21, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb922180965, moduleTitle=格列卫仿制药的未来之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb922180965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261301, encodeId=fc7312613014c, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=原研阿德福韦酯与仿制药治疗慢乙肝1例, objectType=article, longId=21377, objectId=2887213e728, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2887213e728, replyNumber=0, likeNumber=75, createdTime=2013-07-15, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2887213e728, moduleTitle=原研阿德福韦酯与仿制药治疗慢乙肝1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2887213e728)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261300, encodeId=9f9312613009a, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=罗氏认为生物仿制药威胁已推迟, objectType=article, longId=9570, objectId=581595e015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=581595e015, replyNumber=0, likeNumber=61, createdTime=2012-09-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=581595e015, moduleTitle=罗氏认为生物仿制药威胁已推迟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=581595e015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261299, encodeId=d3ef1261299e0, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准吡格列酮的仿制药上市, objectType=article, longId=9180, objectId=b9419180bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9419180bb, replyNumber=0, likeNumber=76, createdTime=2012-08-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9419180bb, moduleTitle=FDA批准吡格列酮的仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9419180bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261298, encodeId=02ee126129860, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Watson公司仿制药Budesonide获FDA批准上市, objectType=article, longId=8584, objectId=24288584e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24288584e0, replyNumber=0, likeNumber=84, createdTime=2012-08-08, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24288584e0, moduleTitle=Watson公司仿制药Budesonide获FDA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24288584e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261297, encodeId=f71b126129e14, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准Actavis公司Ropinirole仿制药上市, objectType=article, longId=6478, objectId=7e4a64e8c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4a64e8c1, replyNumber=0, likeNumber=73, createdTime=2012-05-26, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4a64e8c1, moduleTitle=FDA批准Actavis公司Ropinirole仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4a64e8c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261296, encodeId=ab531261296cb, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=FDA批准氯吡格雷仿制药, objectType=article, longId=6404, objectId=b182640429, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b182640429, replyNumber=0, likeNumber=64, createdTime=2012-05-23, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b182640429, moduleTitle=FDA批准氯吡格雷仿制药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b182640429)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1261295, encodeId=39181261295b3, content=<a href='/topic/show?id=b56025592eb' target=_blank style='color:#2F92EE;'>#仿制药#</a>, objectTitle=Gabapentin口服液仿制药新药申请获得美FDA批准, objectType=article, longId=5994, objectId=9aeb59945c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9aeb59945c, replyNumber=0, likeNumber=62, createdTime=2012-05-07, rootId=0, userName=drwjr, userId=08e964, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9aeb59945c, moduleTitle=Gabapentin口服液仿制药新药申请获得美FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9aeb59945c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

仿制药

2020-05-29

drwjr (审核中...)

前往app查看评论内容

#仿制药#

代文仿制药终获FDA批准

2014-07-04

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药产业2015年市场规模或达5千亿

2014-07-03

drwjr (审核中...)

前往app查看评论内容

#仿制药#

从全球看中国仿制药市场投资机会

2014-06-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

英国法院裁决阿特维斯培美曲塞仿制药不侵犯礼来专利权

2014-05-24

drwjr (审核中...)

前往app查看评论内容

#仿制药#

诺华提请禁止印度百康推出其维格列汀仿制药

2014-04-13

drwjr (审核中...)

前往app查看评论内容

#仿制药#

梯瓦Evista仿制药获FDA批准

2014-03-07

drwjr (审核中...)

前往app查看评论内容

#仿制药#

仿制药质量一致性评价马上推进

2014-02-19

drwjr (审核中...)

前往app查看评论内容

#仿制药#

罗氏禁止仿制药对手使用赫赛汀进行对照

2014-02-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

全球仿制药巨头为何退出中国

2014-02-11

drwjr (审核中...)

前往app查看评论内容

#仿制药#

巨头卡位：谁将抢下全球仿制药**把交椅？

2014-01-19

drwjr (审核中...)

前往app查看评论内容

#仿制药#

品牌仿制药：迎来行业发展新契机

2013-12-14

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA向仿制药商增收费用印度制药商成本增加

2013-08-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

格列卫仿制药的未来之路

2013-07-21

drwjr (审核中...)

前往app查看评论内容

#仿制药#

原研阿德福韦酯与仿制药治疗慢乙肝1例

2013-07-15

drwjr (审核中...)

前往app查看评论内容

#仿制药#

罗氏认为生物仿制药威胁已推迟

2012-09-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准吡格列酮的仿制药上市

2012-08-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Watson公司仿制药Budesonide获FDA批准上市

2012-08-08

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准Actavis公司Ropinirole仿制药上市

2012-05-26

drwjr (审核中...)

前往app查看评论内容

#仿制药#

FDA批准氯吡格雷仿制药

2012-05-23

drwjr (审核中...)

前往app查看评论内容

#仿制药#

Gabapentin口服液仿制药新药申请获得美FDA批准

2012-05-07

科室
- - 订阅+
  - 更多科室
工具
服务